Tags

Type your tag names separated by a space and hit enter

[Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687].
Acta Med Port. 2017 Mar 31; 30(3):163-168.AM

Abstract

Regardless the psoriasis subtype, up to 79% of people with this skin condition present scalp involvement, which is often the first site to show symptoms of the disease. In addition to being itchy, the red and scaly lesions are usually easy to see, and may be embarrassing. Topical therapy is usually the first line of treatment; however the wide array of available interventions can make the choice difficult, and may even lead to an inadequate treatment. The objective of this review was to evaluate the efficacy and safety of topical treatments for scalp psoriasis. A systematic review was performed according to the methodology recommended by Cochrane in order to evaluate the clinical severity of psoriasis, quality of life, and adverse events that led to treatment discontinuation. To evaluate this, 59 studies were included, with a total of 11 561 participants, and 15 comparisons were made between the various drugs and application vehicles tested. The principal conclusion is that corticosteroids of high or very high potency are more effective than vitamin D. The combination of a corticosteroid with vitamin D has only a marginal benefit over corticosteroid monotherapy, but is superior to vitamin D alone. Given the similar safety profile and only marginal benefit of the combination of corticosteroid with vitamin D over the corticosteroid alone, topical corticosteroid monotherapy appears to be fully acceptable for short-term therapy of scalp psoriasis.

Authors+Show Affiliations

Serviço de Dermatologia. Hospital de Santa Maria. Lisboa. Portugal.Laboratório de Farmacologia Clínica e Terapêutica. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Clinical Pharmacology Unit. Instituto de Medicina Molecular. Lisboa. Portugal. Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.Laboratório de Farmacologia Clínica e Terapêutica. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Clinical Pharmacology Unit. Instituto de Medicina Molecular. Lisboa. Portugal. Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Centro Colaborador Português da Rede Cochrane Iberoamericana. Lisboa. Portugal.

Pub Type(s)

Comparative Study
Journal Article
Review
Systematic Review

Language

por

PubMed ID

28550824

Citation

Queirós, Catarina Soares, et al. "[Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687]." Acta Medica Portuguesa, vol. 30, no. 3, 2017, pp. 163-168.
Queirós CS, Duarte GS, Costa J, et al. [Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687]. Acta Med Port. 2017;30(3):163-168.
Queirós, C. S., Duarte, G. S., Costa, J., & Vaz-Carneiro, A. (2017). [Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687]. Acta Medica Portuguesa, 30(3), 163-168. https://doi.org/10.20344/amp.8910
Queirós CS, et al. [Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687]. Acta Med Port. 2017 Mar 31;30(3):163-168. PubMed PMID: 28550824.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687]. AU - Queirós,Catarina Soares, AU - Duarte,Gonçalo Silva, AU - Costa,João, AU - Vaz-Carneiro,António, Y1 - 2017/03/31/ PY - 2017/03/01/received PY - 2017/03/01/accepted PY - 2017/5/29/entrez PY - 2017/5/30/pubmed PY - 2018/5/31/medline SP - 163 EP - 168 JF - Acta medica portuguesa JO - Acta Med Port VL - 30 IS - 3 N2 - Regardless the psoriasis subtype, up to 79% of people with this skin condition present scalp involvement, which is often the first site to show symptoms of the disease. In addition to being itchy, the red and scaly lesions are usually easy to see, and may be embarrassing. Topical therapy is usually the first line of treatment; however the wide array of available interventions can make the choice difficult, and may even lead to an inadequate treatment. The objective of this review was to evaluate the efficacy and safety of topical treatments for scalp psoriasis. A systematic review was performed according to the methodology recommended by Cochrane in order to evaluate the clinical severity of psoriasis, quality of life, and adverse events that led to treatment discontinuation. To evaluate this, 59 studies were included, with a total of 11 561 participants, and 15 comparisons were made between the various drugs and application vehicles tested. The principal conclusion is that corticosteroids of high or very high potency are more effective than vitamin D. The combination of a corticosteroid with vitamin D has only a marginal benefit over corticosteroid monotherapy, but is superior to vitamin D alone. Given the similar safety profile and only marginal benefit of the combination of corticosteroid with vitamin D over the corticosteroid alone, topical corticosteroid monotherapy appears to be fully acceptable for short-term therapy of scalp psoriasis. SN - 1646-0758 UR - https://www.unboundmedicine.com/medline/citation/28550824/[Analysis_of_the_Cochrane_Review:_Topical_Treatments_for_Scalp_Psoriasis__Cochrane_Database_Syst_Rev__2016 L2 - http://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8910 DB - PRIME DP - Unbound Medicine ER -